Sep 30 |
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
|
Sep 26 |
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
|
Sep 25 |
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
|
Sep 18 |
GRI Bio Participates in Virtual Investor KOL Connect Segment
|
Sep 5 |
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
Sep 4 |
GRI Bio to Present at the 2024 European Respiratory Congress
|
Aug 15 |
GRI Bio reports Q2 results
|
Aug 14 |
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
Jul 15 |
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
|
Jul 11 |
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
|